Long-Term Follow-Up in Patients With Chronic Myeloid Leukemia Treated With Ponatinib in a Real-World Cohort: Safety and Efficacy Analysis

CONCLUSION: CV toxicity was consistent with clinical trials and other real-world registries. Older age, hypercholesterolemia and a SCORE risk >2% were significantly associated with higher risk of AOEs. Controlling CV risk factors and reducing doses at optimal time points may help to optimize ponatinib use in daily practice.PMID:37973457 | DOI:10.1016/j.clml.2023.10.008

Source: Clinical Lymphoma and Myeloma - November 16, 2023 Category: Cancer & Oncology Authors: Mar ía José Mela Osorio Beatriz Moiraghi Mar ía Victoria Osycka Miguel A Pavlovsky Ana In és Varela Georgina Emilia Bendek Del Prete Mar ía Fernanda Tosin Mariel Ana P érez Mar ía Elisa Riva Roxana Ram írez Berrios Isolda Fern ández Federico Sack Source Type: research